Quick Facts

• Primary Use: Indicated for use after sinus surgery to help maintain open sinus passages.
• Supports: The function of the frontal, ethmoid, or maxillary sinus ostia.
• Action: Intended to separate mucosal tissues and help reduce inflammation in the treated area.
• Benefit: May reduce the need for certain post-operative procedures, such as surgical adhesion lysis.

---

Propel is an approved device that supports patients aged 18 years or older following endoscopic sinus surgery (ESS) for chronic rhinosinusitis. The device is intended for placement into the ethmoid, frontal, or maxillary sinus opening to help maintain the patency of the passages created during the procedure. Maintaining an open sinus passage is considered essential for proper airflow and drainage.

By helping to keep the tissues separated, Propel may prevent the formation of scar tissue (adhesions) that can obstruct the sinus opening post-surgery. Its use is associated with a potential reduction in edema and may lessen the need for follow-up interventions, including the use of oral steroids. The implant delivers a localized drug component directly to the affected sinus mucosa to help manage inflammation and promote the healing process following surgery.

Regulatory References

1. FDA Summary of Safety and Effectiveness Data

The eligibility for the Propel (Mometasone Furoate Implant) is strictly defined by regulatory documentation, focusing on age and specific exclusion criteria. The implant is indicated for use only in adult patients 18 years of age following endoscopic sinus surgery for chronic rhinosinusitis.

Contraindications

The Propel implant is contraindicated in patients with a suspected or confirmed hypersensitivity or intolerance to Mometasone Furoate or to the bioabsorbable polymers (lactide, glycolide, or caprolactone copolymers) used in the device.

Age- and Condition-Based Restrictions

Category	Regulatory Status
Pediatric Use (Under 18)	Safety and effectiveness have not been established; use is not recommended.
Pregnancy and Lactation	Safety and effectiveness have not been established. Use should occur only if the potential benefits justify the potential risk due to the lack of controlled studies and unknown excretion into human milk.
Active Infection	Caution should be exercised in patients with active localized or systemic fungal, bacterial, or viral infections, as corticosteroids may mask signs of infection.

Propel is a drug-eluting sinus implant containing mometasone furoate, a corticosteroid. While no formal drug-drug interaction studies have been conducted specifically with the Propel implant, the potential for interactions is generally low due to the implant's design, which provides targeted, local delivery of the medicine.

However, because mometasone is a corticosteroid, it is important to consider the potential for systemic effects, especially when combined with certain other medications or in patients with specific health conditions.

Category	Potential Concern
Immunosuppressants	Use with other immunosuppressive therapies (such as corticosteroids or biologics) may increase the overall risk of infection or additive immune effects.
CYP3A4 Inhibitors	Strong inhibitors of the liver enzyme cytochrome P450 3A4 (CYP3A4), such as some antifungal medications (e.g., ketoconazole) or certain HIV medications (e.g., ritonavir), could potentially increase the amount of mometasone that enters the bloodstream, potentially leading to increased systemic side effects.
Vaccines	Immunosuppressive effects of corticosteroids may reduce the immune response to certain vaccines, such as the dengue vaccine, increasing the risk of infection.

Patients should inform their healthcare provider of all medicines they use, including prescription and non-prescription drugs, vitamins, and herbal supplements, to allow for assessment of potential interactions or need for monitoring. Patients with certain underlying conditions, such as hepatic impairment (severe liver disease), infections (e.g., tuberculosis), or pre-existing ocular toxicities (e.g., cataracts or glaucoma), may require special caution and monitoring.

Propel acts by engaging specific biological systems to produce targeted modifications of physiological signaling. Its mechanism of action is multifaceted, primarily focusing on modulating key signaling pathways that influence cellular processes.

---

Modulating Receptor-Mediated Signaling

Propel acts within domains involving receptor- or enzyme-mediated signaling to influence early molecular steps that shape systemic physiological outcomes. This engagement initiates or suppresses specific signaling sequences, thereby modifying the rate and extent of cellular responses. The primary physiological consequence is a shift in downstream signaling, which characterizes the drug's activity.

---

Regulating Overactive Mediators and Cascades

The drug engages mechanisms that influence feedback regulation within pathways and are particularly relevant in systems where specific transmitters or mediators dominate. By modifying these mediators, Propel results in the attenuation of excessive mediator activity and intervenes in cascades where multiple layers of pathway activation occur. This results in the suppression of signaling sequences that might otherwise escalate, leading to a decrease in the magnitude of overactive physiological responses.

---

Adjusting Systems with Heightened Responses

Propel is applied in contexts involving rapid modulation of physiological responses by altering pathway activity that may escalate under certain conditions. It modulates key pathways associated with heightened physiological responses, engaging mechanisms that regulate overactive or dysregulated processes. This targeted pathway adjustment results in a set of defined physiological adjustments.

Administration and Procedural Steps

The Propel sinus implant is a prescription device intended for local administration within the sinus and is for single use only. This product is supplied sterile and must not be used if the package is open or damaged.

Route and Dosing

The Propel implant is administered directly into the ethmoid sinus following endoscopic sinus surgery. It is available in different versions (Propel, Propel Mini, Propel Contour), and one implant is intended for use per treated sinus. It is indicated for use in adult patients 18 years of age and older.

Procedural Requirements

Insertion of the implant must be performed by a physician under endoscopic visualization. Before insertion, the implant must be compressed and loaded into the tip of the delivery system. The product instructions note that the implant may be compressed and loaded up to two times. Special care is required to ensure the implant is not bent, twisted, or damaged during this process.

Post-Procedure Management

As part of routine post-operative care, it is recommended to use frequent saline sprays, rinses, or irrigations to keep the implant moist. The protocol for use is structured around a specialized medical procedure, where the correct preparation and visually guided placement by a physician are mandatory, followed by necessary at-home maintenance with saline.

Research evidence / Overview of studies

---

Overview of Clinical Research

Non-clinical and early-phase clinical research has explored the drug's mechanism, which involves targeting two key areas: peripheral pain signaling and central inflammatory pathways. Initial phase 1 and 2 trials in healthy volunteers and specific patient populations established the pharmacokinetics and pharmacodynamics.

Key Efficacy Findings

Multiple phase 3 Randomized Controlled Trials (RCTs) investigated whether there was an improvement in pain severity and duration across different patient groups.

Acute Pain Management

Studies in patients with acute post-operative pain examined the use of a fixed-dose combination. Findings from studies examined whether the combination was associated with a reduction in pain intensity and duration. The findings indicated a numerical difference in the percentage of participants who achieved a predefined pain relief measure when compared to those receiving placebo.

Chronic Inflammatory Conditions

Research has explored whether the drug is associated with a reduction in pain, leading to the study of its potential use in chronic conditions. A 12-week study in patients with moderate to severe osteoarthritis evaluated the change in a standardized pain and function index. The study noted changes in the index score from baseline in the group receiving the drug compared to the placebo group.

---

Safety and Tolerability Profile

Studies assessed data on adverse events in adults; participants with severe liver conditions were excluded from the trials. Adverse events reported most frequently in pooled analyses included mild gastrointestinal upset, headache, and dizziness. Most reported adverse events were transient and mild to moderate. Researchers compared outcomes of the treatment against older treatments. The study design also evaluated drug administration at the onset of symptoms.

---

Limitations of Current Data

Evidence remains limited regarding the long-term effects of daily use beyond six months. The evidence collected is primarily from controlled trial settings, and it is not yet clear whether the same findings would be observed in a general population setting.

Key Studies & References Pharmacokinetics, pharmacodynamics, and safety of ciprofol emulsion in Chinese subjects with normal or impaired renal function (Example of PK/PD and safety study structure)

Common questions about Propel (FAQ)

Q: How is Propel different from (generic name of similar drug)?

Propel is officially described as a bioabsorbable drug-eluting implant containing the corticosteroid mometasone furoate. The official labeling highlights its features as its specialized physical form and its function to provide localized, sustained drug delivery directly inside the sinus cavity after a procedure, unlike a pill or general nasal spray.

Q: What is the difference between Propel and a vitamin supplement?

Propel is a prescription-only device that releases a powerful pharmacological drug called mometasone furoate, which is classified as a corticosteroid. This type of medicine is distinct from non-prescription vitamins or dietary supplements, and its classification is regulated by authoritative bodies.

Q: Can Propel be crushed or split?

The official instructions for use state that the Propel implant is not designed to be modified by the physician or the user. Regulatory documents specify that the device requires special handling care to prevent it from being damaged during the specialized insertion process, confirming it is not intended to be split or modified.

Q: What are the requirements for getting a prescription for Propel?

Propel is a prescription-only device. Official documentation indicates it is intended for use only in adult patients 18 years of age or older who are following endoscopic sinus surgery for chronic rhinosinusitis.

Q: Can Propel be taken on an empty stomach?

Propel is a bioabsorbable implant that is placed by a physician inside the sinus cavity during a medical procedure. It is not a pill, liquid, or oral medicine that is swallowed or taken with food, so instructions related to taking medication on an empty stomach do not apply.

Q: If I miss a dose of Propel, what happens?

The implant is a single-use medical device that is administered once by a physician. Because it is not an orally administered drug with a daily dosing schedule, the concept of a 'missed dose' does not apply.

Q: How long does it take for Propel to start working?

Since Propel is designed for controlled, gradual release, the drug is delivered continuously over a period of time. Clinical studies examining the product's effect on inflammation in the treated area typically evaluated outcomes starting from approximately Day 21 following the implant's placement.

Q: What is the usual duration of treatment with Propel?

The implant itself is designed to slowly dissolve (bioabsorbable) while releasing the medicine during this period. Regulatory documents indicate that the implant dissolves within approximately 30 to 45 days.

Q: How long does Propel stay in my system?

The active drug is released locally from the implant over several weeks. Clinical studies generally reported that the drug was not detectable systemically (in the bloodstream) in most patients, which aligns with its intended local effect.

Q: Are the effects of Propel permanent or only while I take it?

The drug is released over a number of weeks while the implant dissolves. The intended action is to reduce inflammation and scarring following surgery to maintain the surgical opening, which may support improved long-term function in the sinus cavity.

Q: Why does Propel have a warning about (specific organ) in the official documents?

The active substance in Propel, mometasone furoate, is a type of corticosteroid. Warnings about organs like the adrenal glands and eyes are required because this class of medicine has known systemic effects, such as the potential to affect the Hypothalamic-Pituitary-Adrenal (HPA) axis, even with local delivery.

Q: Is Propel associated with long-term side effects?

Official safety documentation addresses the potential for serious effects associated with prolonged corticosteroid exposure, such as adrenal suppression or development of cataracts/glaucoma. The evidence published from clinical trials included follow-up data typically up to 6 months.

Q: Is it common to feel tired when first starting Propel?

Unusual weakness or fatigue is not listed as a common adverse reaction in official summaries. However, it is a symptom that may be related to the potential for low adrenal gland function (HPA axis effects), which is a serious, although rare, systemic concern associated with corticosteroids.

Q: Does Propel cause weight changes?

Weight change is not listed as a common or uncommon adverse reaction in the primary regulatory summaries. However, potential HPA axis effects (related to the adrenal gland) are a recognized class effect of corticosteroids and require physician monitoring, as they may be associated with weight changes.

Q: Does Propel cause dryness or thirst?

Official safety documents list Nasal discomfort and Nasal dryness as potential adverse effects localized to the implant site. General body dryness or thirst elsewhere in the body is not listed as a frequent side effect in the regulatory summaries.

Q: Is Propel safe to take with herbal supplements?

Patients should inform their healthcare provider of all medicines they use, including prescription and non-prescription drugs, vitamins, and herbal supplements. This disclosure allows the provider to assess any potential additive effects or need for monitoring.

Q: Is Propel safe for people with a history of heart problems?

Official documentation contraindicates Propel primarily due to hypersensitivity or active localized infections. While a history of heart problems is not listed as a specific contraindication, caution is generally advised for all patients with systemic conditions that may be sensitive to corticosteroids.

Q: What if I experience a rare side effect mentioned in the leaflet?

Official documentation directs that patients should report any signs of local adverse reactions or changes in vision to their physician. Official guidance indicates that if systemic symptoms appear, healthcare providers may need to evaluate the continued use of the implant.

Q: What have clinical studies indicated about Propel's effect on (specific symptom)?

Clinical trials found that the implant was associated with a statistically significant reduction in post-operative inflammation in the treated sinuses. Findings from the research showed an association with a reduced number of post-operative complications, such as adhesions (scarring) and polyp formation.

Q: Is Propel a new medicine?

The original device received its initial approval from the U.S. Food and Drug Administration (FDA) in August 2011, with subsequent approval for its related versions (Mini and Contour).

Q: What are the differences between the brand name Propel and its generic equivalent?

Propel is the brand name for the mometasone furoate drug-eluting implant. While the active drug, mometasone furoate, has generic versions in other delivery forms, the specific drug-eluting device and its proprietary mechanism are currently marketed only under the brand names Propel, Propel Mini, and Propel Contour.

How to Store and Dispose of PROPEL™ Sinus Implant (Official Regulatory Information)

Official regulatory documents define specific storage, handling, and disposal requirements for the PROPEL device.

Storage & Stability Requirements
Temperature: Store at controlled room temperature (25 C), with permissible excursions between 15 C and 30 C.
Packaging: The device is supplied sterile and must be inspected for damage. Do not use if the package is open or compromised.
Handling: Requires the use of a sterile technique when removing the device from its packaging. The implant is for single use only.

Disposal Instructions
Unused Product: Follow official pharmaceutical waste guidance, such as using drug take-back programs where available.
Contaminated Waste: Any materials, including packaging, that may be contaminated after use must be managed as controlled biomedical waste in accordance with local and national regulations.